High 4-gene inflammatory score	Mesothelioma	High 4-gene inflammatory score	Mesothelioma	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
CD8 expression	Prostate Cancer	CD8 expression	Prostate Cancer	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B
CD8 expression	Melanoma	CD8 expression	Melanoma	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
CD8 overexpression	Non Small Cell Lung Cancer	CD8 overexpression	Non Small Cell Lung Cancer	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3
CD8 overexpression	Melanoma	CD8 overexpression	Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
PD-L1 overexpression + CD8 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression + CD8 overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-1 overexpression + CD8 positive	Non Small Cell Lung Cancer	PD-1 overexpression + CD8 positive	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
CD8-H	Triple Negative Breast Cancer	CD8-H	Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CD8 expression	Urothelial Cancer	CD8 expression	Urothelial Cancer	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3
TCF7 overexpression + CD8 overexpression	Melanoma	TCF7 overexpression + CD8 overexpression	Melanoma	PD-L1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor + CTLA4 inhibitor Sensitive : C3	PD-L1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor + CTLA4 inhibitor Sensitive : C3
CD8 overexpression	Non Small Cell Lung Cancer	CD8 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CD8 positive	Non Small Cell Lung Cancer	CD8 positive	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
CD8 expression	Melanoma	CD8 expression	Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CD8 expression	Melanoma	CD8 expression	Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
CD8 expression	Renal Cell Carcinoma	CD8 expression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PD-L1 expression + CD8 negative + GZMB negative	Non Small Cell Lung Cancer	PD-L1 expression + CD8 negative + GZMB negative	Non Small Cell Lung Cancer	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3
CD8 positive	Triple Negative Breast Cancer	CD8 positive	Triple Negative Breast Cancer	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3	camrelizumab + SHR 1020 Sensitive: C3 – Early Trials camrelizumab + SHR 1020 Sensitive : C3
PD-L1 expression + CD8 positive	Ovarian Cancer	PD-L1 expression + CD8 positive	Ovarian Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
TNFRSF9 positive + CD8 positive	Clear Cell Renal Cell Carcinoma	TNFRSF9 positive + CD8 positive	Clear Cell Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CD8 positive	Non Small Cell Lung Cancer	CD8 positive	Non Small Cell Lung Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
CD8 overexpression	Breast Cancer	CD8 overexpression	Breast Cancer	paclitaxel + epirubicin Sensitive: C3 – Early Trials paclitaxel + epirubicin Sensitive : C3	paclitaxel + epirubicin Sensitive: C3 – Early Trials paclitaxel + epirubicin Sensitive : C3
CD8 overexpression	Bladder Cancer	CD8 overexpression	Bladder Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
CD8 expression	Solid Tumor	CD8 expression	Solid Tumor	TAB004 Sensitive: C3 – Early Trials TAB004 Sensitive : C3	TAB004 Sensitive: C3 – Early Trials TAB004 Sensitive : C3
CD8 elevation + BRAF V600	Melanoma	CD8 elevation + BRAF V600	Melanoma	dacarbazine Sensitive: C3 – Early Trials dacarbazine Sensitive : C3	dacarbazine Sensitive: C3 – Early Trials dacarbazine Sensitive : C3
CD8-H	Breast Cancer	CD8-H	Breast Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
CD8 overexpression	Melanoma	CD8 overexpression	Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CD8 overexpression	Melanoma	CD8 overexpression	Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CD8 underexpression + HAVCR2 overexpression	Melanoma	CD8 underexpression + HAVCR2 overexpression	Melanoma	PD1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + CTLA4 inhibitor Sensitive : C3	PD1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + CTLA4 inhibitor Sensitive : C3
CD8 underexpression + HAVCR2 overexpression	Melanoma	CD8 underexpression + HAVCR2 overexpression	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
CD8 underexpression + HAVCR2 overexpression	Melanoma	CD8 underexpression + HAVCR2 overexpression	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
CD8 overexpression	Bladder Cancer	CD8 overexpression	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CD8 expression	Esophageal Squamous Cell Carcinoma	CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3

CD8 (cluster of differentiation 8)

Associations(42)

Associations
(42)